A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

Prior treatment

• Having undergone major surgery or significant trauma within 4 weeks prior to the first use of the study drug ;
• Severe infection occurred within 4 weeks before the first administration.
• The first study of arterial / venous thrombosis events within 3 months before medication was conducted.

Other illness

• Other malignant tumors occurred within 5 years before the first administration, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, ductal carcinoma in situ after radical resection, and papillary thyroid carcinoma after radical resection.
• Subjects with a history of interstitial pneumonia or suspected interstitial pneumonia by imaging examination during screening ; or other lung diseases that seriously affect lung function ;
• Have serious cardiovascular and cerebrovascular diseases
• Have a history of immunodeficiency, including HIV test positive ;
• There is active hepatitis B or hepatitis C ;

Other

• Subjects with active central nervous system ( CNS ) metastasis ;
• Subjects with active central nervous system ( CNS ) metastasis ;

• Age 18 years old to 75 years old ( including both ends ), regardless of gender ;
• Subjects with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer ;
• Histological specimens confirmed the presence of KRAS G12 C mutation ;
• Participants who have failed at least one line of systemic anti-tumor treatment in the locally advanced or metastatic stage. Previous systemic anti-tumor treatment should include : platinum-containing double-agent chemotherapy and immune checkpoint inhibitor therapy ( synchronous or sequential, except that the researchers determine that it is not suitable for immune checkpoint inhibitors or chemotherapy ) ;
• At least one measurable lesion conforming to the definition of RECIST v1.1 standard ;
• ECOG physical score 0-1 points ;
• Expected survival time ≥ 12 weeks ;
• Have adequate bone marrow and organ function
• Subjects were required to give informed consent to this study before the trial and voluntarily sign a written informed consent form.